pCPA Activity Overview
Status | Total Negotiations | Summary |
---|---|---|
Active Negotiations | 49 | Non-oncology: 32 Oncology: 17 |
Under Consideration for Negotiation | 19 | Non-oncology: 14 Oncology: 5 |
Completed Negotiations | 756 | With Letter of Intent: 651 Without agreement: 105 |
Negotiations That Were Not Pursued | 108 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
Brand Name | Manufacturer | Indication | Engagement Date |
---|---|---|---|
Omlyclo | Celltrion Healthcare Canada Ltd. | Multiple Indications | |
TBC (infliximab) | Celltrion Healthcare Canada Ltd. | Multiple Indications | |
Venclexta | AbbVie Corporation | In combination with Gazyva, for the treatment of patients with previously untreated chronic lymphocytic leukemia | |
Gazyva | Hoffmann-La Roche Ltd. | In combination with Venclexta, for the treatment of patients with previously untreated chronic lymphocytic leukemia | |
Repatha | Amgen Canada Inc. | Atherosclerotic cardiovascular disease | |
Opdivo-Yervoy | Bristol Myers Squibb Canada Inc. | In combination, for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma when patients progress during or within 6 months of adjuvant PD-1 therapy. | |
Cabtreo | Bausch Health, Canada Inc. | Acne Vulgaris | |
Ultomiris | Alexion Pharma GmbH | Generalized myasthenia gravis (gMG) | |
Carvykti | Janssen Inc. | For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide. | |
Fruzaqla | Takeda Canada Inc. | For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemother | |
Nextstellis | Searchlight Pharma Inc. | Prevention of Pregnancy | |
Enhertu (pTAP negotiation) | AstraZeneca Canada Inc. | As monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen |